You are here

Is hematopoietic cell transplantation in CML still relevant in 2022?

Categories:

I believe it is.

Some stop responding and they run out of TKI options. Some experience side effects severe enough to stop a particular TKI and does not respond to others.

And the accumulation of something so toxic into our bodies poses its own dangers. This is why I use the sauna on a regular basis - and I encourage those without contra-indications to explore the subject.

This is why I suspect TKI pairing or TKI cycling should be given serious thought.

SCT is not without it's potential dangers. The GVHD (graft vs host disease) sounds terrifying and my limited research indicates cataracts is a very real possibilty for those who undergo the procedure.

I'm one of those unfortunates who is being considered for a transplant. Diagnosed November 2016, failed Imatinib, allergic to Bosutinib, pcr 0.03 on Dasatininb, unsuitable for Asciminib as platelets very low and needing support. Now on Ponatinib for the last month but cytogenetics revealed an extra mutation as cell counts fell off a 'cliff'. 

My haematologist has always regarded the transplant option as unsuitable because of the dangers but we have run out of options. Having discussed it with her colleagues, they think it unlikely that even the mighty Ponatinib will help though it might give me some breathing space.

Not looking forward to the prospect but I may not be a suitable candidate (over 65) or we may not find a suitable donor.